SCHEMBL5544040

SCHEMBL5544040

[CH2]c1ccc2[nH]c(=O)oc2c1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OGT O15294 1/20 0.37
NOS1 P29475 5/20 0.37
NOS2 P35228 4/20 0.36
F2 P00734 1/20 0.35
CFD P00746 1/20 0.35
NOS3 P29474 3/20 0.33
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33
ADRA2A P08913 1/20 0.33
TSHR P16473 1/20 0.33
THPO P40225 1/20 0.33
BLM P54132 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
MAOA P21397 1/20 0.32
ACHE P22303 1/20 0.32
MAOB P27338 1/20 0.32
DAO P14920 1/20 0.32
KMO O15229 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544046 0.79 NOS1 (0.46) OGTNOS1NOS2F2CFD
SCHEMBL5541858 0.78 OGT (0.37) OGTNOS1NOS2F2CFD
SCHEMBL5542425 0.78 NOS1 (0.41) OGTNOS1NOS2F2CFD
SCHEMBL5537226 0.73 OGT (0.48) OGTNOS1NOS2F2CFD
SCHEMBL18586859 0.70 OGT (0.37) OGTNOS1NOS2F2CFD
SCHEMBL14534370 0.70 NOS1 (0.44) OGTNOS1NOS2F2CFD
SCHEMBL5544210 0.70 MCL1 (0.46) OGTNOS1NOS2NOS3LMNA
SCHEMBL2149176 0.69 OGT (0.48) OGTF2CFDDAOHTR1A
SCHEMBL31381757 0.68 NOS1 (0.33) OGTNOS1NOS2NOS3
SCHEMBL23137519 0.67 NOS1 (0.48) OGTNOS1NOS2F2CFD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 OGT 1633/4885NOS1 553/4885NOS2 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.